SHR-A1904

DRUG6 trials

Conditions

Advanced Pancreatic CancerAdvanced Solid CancerAdvanced Solid TumorsCLDN18.2-positive Adenocarcinoma of the Gastroesophageal JunctionColorectal Cancer MetastaticGastric CancerHER2 + Gastric CancerPD-L1 Positive

Phase 1

A Study of SHR-A1904 in Patients With Advanced Solid Cancer

Active, not recruitingNCT04877717

Shanghai Hengrui Pharmaceutical Co., Ltd.Advanced Solid Cancer

Start: 2021-07-01End: 2025-12-01Updated: 2025-03-25

A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer

NCT04928625

Shanghai Hengrui Pharmaceutical Co., Ltd.Advanced Pancreatic Cancer

Start: 2021-08-06End: 2023-12-31Target: 75Updated: 2021-08-24

A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS

RecruitingNCT05277168

Jiangsu HengRui Medicine Co., Ltd.Advanced Solid Tumors

Start: 2022-05-30End: 2026-05-01Target: 83Updated: 2026-05-22

Phase 2

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Not yet recruitingNCT06881017

China Medical University, ChinaCLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, Gastric Cancer, HER2 + Gastric Cancer +1

Start: 2025-05-01End: 2029-11-01Target: 140Updated: 2025-03-18

SHR-A1904 in Advanced Colorectal Cancer: an Exploratory Study

Not yet recruitingNCT07700719

Peking University Cancer Hospital & InstituteColorectal Cancer Metastatic

Start: 2026-07-28End: 2028-04-28Target: 17Updated: 2026-07-14

Phase 3

SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

RecruitingNCT06649292

Shanghai Hengrui Pharmaceutical Co., Ltd.Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Start: 2024-11-22End: 2028-03-20Target: 524Updated: 2026-05-15

Related Papers

A global phase 1/2a trial of SHR-A1904, a CLDN18.2-targeting ADC, in advanced solid tumors expressing CLDN18.2.

Journal of Clinical Oncology2026-05-28

The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial.